Company Page
Most Recent Insiders Activity
| Transaction Date | Company Name | Insider Name (Title) | Activity | Stock | Acquired or Disposed | Shares | Price range | Amount |
|---|---|---|---|---|---|---|---|---|
| 2024-04-24 | Intra-Cellular Therapies, Inc. | Mates Sharon
(Chairman and CEO) |
M | Common Stock | A | 20020 | $16.86 - $17.57 | $345,617 |
| 2024-03-07 | Intra-Cellular Therapies, Inc. | Mates Sharon
(Chairman, President & CEO) |
S | Common Stock | D | 61277 | $64.80 - $67.33 | $4,048,397 |
| 2024-03-07 | Intra-Cellular Therapies, Inc. | Hineline Lawrence J.
(SVP of Finance, CFO) |
S | Common Stock | D | 23253 | $65.28 - $67.32 | $1,542,144 |
| 2024-03-10 | Intra-Cellular Therapies, Inc. | Hineline Lawrence J.
(SVP of Finance, CFO) |
M | Common Stock | A | 4539 | $56.73 - $56.73 | $257,497 |
| 2024-03-07 | Intra-Cellular Therapies, Inc. | Halstead Michael
(EVP and General Counsel) |
S | Common Stock | D | 20477 | $65.82 - $66.81 | $1,353,233 |
| 2024-03-07 | Intra-Cellular Therapies, Inc. | Neumann Mark
(EVP, Chief Commercial Officer) |
S | Common Stock | D | 20477 | $65.11 - $66.95 | $1,356,108 |
| 2024-03-07 | Intra-Cellular Therapies, Inc. | Durgam Suresh K.
(EVP, Chief Medical Officer) |
S | Common Stock | D | 10162 | $65.06 - $66.96 | $672,788 |
| 2024-02-27 | Intra-Cellular Therapies, Inc. | VAN NOSTRAND ROBE...
(Director) |
S | Common Stock | D | 20000 | $72.71 - $73.14 | $1,458,649 |
| 2024-02-27 | Intra-Cellular Therapies, Inc. | VAN NOSTRAND ROBE...
(Director) |
M | Common Stock | A | 20000 | $18.56 - $18.56 | $371,200 |
| 2024-02-26 | Intra-Cellular Therapies, Inc. | Halstead Michael
(EVP and General Counsel) |
S | Common Stock | D | 7907 | $68.54 - $70.13 | $549,783 |
| 2024-02-26 | Intra-Cellular Therapies, Inc. | Durgam Suresh K.
(EVP, Chief Medical Officer) |
S | Common Stock | D | 4112 | $69.38 - $71.02 | $288,534 |
| 2024-02-26 | Intra-Cellular Therapies, Inc. | Neumann Mark
(EVP, Chief Commercial Officer) |
S | Common Stock | D | 7907 | $68.03 - $71.18 | $554,490 |
| 2024-02-26 | Intra-Cellular Therapies, Inc. | MARCUS JOEL S
(Director) |
S | Common Stock | D | 26328 | $67.83 - $69.60 | $1,808,252 |
| 2024-02-26 | Intra-Cellular Therapies, Inc. | MARCUS JOEL S
(Director) |
M | Common Stock | A | 36757 | $43.45 - $55.48 | $1,798,678 |
| 2024-02-02 | Intra-Cellular Therapies, Inc. | Halstead Michael
(EVP and General Counsel) |
S | Common Stock | D | 11860 | $66.37 - $67.17 | $787,719 |
| 2024-02-01 | Intra-Cellular Therapies, Inc. | Halstead Michael
(EVP and General Counsel) |
A | Common Stock | A | 11860 | $0.00 - $0.00 | $0 |
| 2024-02-02 | Intra-Cellular Therapies, Inc. | Mates Sharon
(Chairman, President & CEO) |
S | Common Stock | D | 33885 | $66.70 - $67.42 | $2,272,693 |
| 2024-02-01 | Intra-Cellular Therapies, Inc. | Mates Sharon
(Chairman, President & CEO) |
A | Common Stock | A | 33885 | $0.00 - $0.00 | $0 |
| 2024-02-02 | Intra-Cellular Therapies, Inc. | Neumann Mark
(EVP, Chief Commercial Officer) |
S | Common Stock | D | 11860 | $66.67 - $67.49 | $796,366 |
| 2024-02-01 | Intra-Cellular Therapies, Inc. | Neumann Mark
(EVP, Chief Commercial Officer) |
A | Common Stock | A | 11860 | $0.00 - $0.00 | $0 |
| 2024-02-02 | Intra-Cellular Therapies, Inc. | Hineline Lawrence J.
(SVP of Finance, CFO) |
S | Common Stock | D | 11183 | $66.61 - $67.35 | $745,035 |
| 2024-02-01 | Intra-Cellular Therapies, Inc. | Hineline Lawrence J.
(SVP of Finance, CFO) |
A | Common Stock | A | 11183 | $0.00 - $0.00 | $0 |
| 2024-02-02 | Intra-Cellular Therapies, Inc. | Durgam Suresh K.
(EVP, Chief Medical Officer) |
S | Common Stock | D | 6167 | $66.69 - $67.49 | $414,354 |
| 2024-02-01 | Intra-Cellular Therapies, Inc. | Durgam Suresh K.
(EVP, Chief Medical Officer) |
A | Common Stock | A | 11860 | $0.00 - $0.00 | $0 |
| 2024-01-16 | Intra-Cellular Therapies, Inc. | Mates Sharon
(Chairman, President & CEO) |
S | Common Stock | D | 191362 | $65.19 - $67.76 | $12,680,889 |
| 2024-01-16 | Intra-Cellular Therapies, Inc. | Mates Sharon
(Chairman, President & CEO) |
M | Common Stock | A | 191362 | $16.86 - $16.86 | $3,226,362 |
| 2024-01-11 | Intra-Cellular Therapies, Inc. | Halstead Michael
(EVP and General Counsel) |
S | Common Stock | D | 50000 | $66.31 - $67.80 | $3,341,696 |
| 2024-01-11 | Intra-Cellular Therapies, Inc. | Halstead Michael
(EVP and General Counsel) |
M | Common Stock | A | 50000 | $12.73 - $23.94 | $680,049 |
| 2024-01-02 | Intra-Cellular Therapies, Inc. | Durgam Suresh K.
(EVP, Chief Medical Officer) |
S | Common Stock | D | 62282 | $70.41 - $71.77 | $4,397,112 |
| 2024-01-02 | Intra-Cellular Therapies, Inc. | Durgam Suresh K.
(EVP, Chief Medical Officer) |
M | Common Stock | A | 62282 | $19.87 - $19.87 | $1,237,543 |
| 2023-12-31 | Intra-Cellular Therapies, Inc. | VAN NOSTRAND ROBE...
(Director) |
A | Common Stock | A | 76 | $71.62 - $71.62 | $5,443 |
| 2023-11-06 | Intra-Cellular Therapies, Inc. | Neumann Mark
(EVP, Chief Commercial Officer) |
S | Common Stock | D | 42393 | $55.02 - $55.98 | $2,358,151 |
| 2023-11-06 | Intra-Cellular Therapies, Inc. | Neumann Mark
(EVP, Chief Commercial Officer) |
M | Common Stock | A | 26754 | $23.94 - $23.94 | $640,490 |
Activity types
| A | Grant, award or other acquisition |
| C | Conversion of Derivative or Security |
| D | Disposition to the issuer of issuer equity securities |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability |
| G | Bona fide Gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary Transaction |
| J | Other acquisition or disposition |
| K | Transaction in equity swap or instrument with similar characteristics |
| L | Small Acquisition |
| M | Exercise or conversion of derivative security |
| O | Exercise of out-of-the-money derivative security |
| P | Open Market Purchase |
| S | Open Market Sale |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| V | Transaction Voluntarily Reported |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |